Clinical pharmacology of antihypertensive drugs

Cardiology Clinics

Volumn 20, Issue 2, 2002, Pages 265-280

  Ram, C Venkata S ^a,b,d   Fenves, Andrew ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b 3601 Swiss Avenue ^*  (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Dallas Nephrology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANABENZ; GUANADREL; LABETALOL; LOOP DIURETIC AGENT; NIFEDIPINE; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT; VASOPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ESSENTIAL HYPERTENSION; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; HYPOKALEMIA; INSOMNIA; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; WITHDRAWAL SYNDROME; BLOOD PRESSURE; DRUG EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION;

EID: 0035987989     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(01)00008-X     Document Type: Article

References (69)

1. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC VI)
2. Inadequate management of blood pressure in a hypertensive population
3. Pharmocology of diuretics
4. Diuretics in the management of hypertension
5. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults
6. Moderate dosium restriction and various diuretics in the treatment of hypertension: Effects on potassium wastage and blood pressure control
7. Diuretic complications
8. Does diuretic therapy increase the risk of renal cell carcinoma?
9. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
10. β blockade after myocardial infarction
11. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
12. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable engina
13. The impact of ethnicity on response to antihypertensive therapy
14. The effects of antihypertensive agents on serum lipids and lipoproteins
15. 1-adrenergic receptor antagonists for the treatment of hypertension
16. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone
17. Alpha-adrenergic blockade by Prazosin in therapy of essential hypertension
18. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment
19. Implications of discontinuation of doxazosin arm of ALLHAT
20. Intravenous labetalol in acute aortic dissection
21. Labetalol hepatotoxicity
22. Transdermal clonidine
23. Withdrawal syndrome following cessation of guarnabenz therapy
24. Abrupt discontinuation of clonidine therapy
25. On the use of rauwolfia serpentina in high blood pressure
26. Angiotensin-converting enzyme inhibitors
27. Captopril
28. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: A review of clinical investigations
29. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
30. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks
31. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients
32. Use of angiotensin converting enzyme inhibitors as monotherapy and in conbination with diuretics and calcium channel blockers
33. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension
34. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects
35. Hypoglycemia associated with use of inhibitors angiotensin converting enzyme
36. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine
37. Angiotensin II receptor antagonists
38. Angiotensin II antagonists for hypertension: Are there differences in efficacy?
39. Angiotensin II receptors and angiotensin II receptor antagonists
40. Efficacy and tolerability of losartan in hypertensive patients with renal impairment
41. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
42. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
43. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE)
44. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure
45. The role of calcium channel blockers in the treatment of essential hypertension
46. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
47. History and prospects in calcium antagonist research
48. The classification of calcium antagonists and their selection in the treatment of hypertension
49. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine
50. Amlodipine
51. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension
52. Risks of untreated and treated isolated systolic hypertension in the elderly
53. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
54. Calcium antagonists in patients with aneurismal subarachnoid hemorrhage
55. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemorgencies?
56. The risk of myocardial infarction associated with antihypertensive drug therapies
57. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients
58. Grapefruit-felodipine interaction
59. Seville orange juice-felodipine interaction
60. Direct and reflex cardiostimulating effects of hydralazine
61. Direct vasodilators
62. The lupus syndrome induced by hydralazine
63. Minoxidil: A review of its pharmacological properties and therapeutic use
64. Refractory hypertension
65. Hypertension
66. Pericardial effusion associated with minoxidil therapy
67. Vasopeptidase inhibition
68. Vasopeptidase inhibition: Cardiovascular therapy for the new millennium?
69. Fixed-dose combination vs monotherapy in hypertension